TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-1943

Related search